AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01834703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU
Description: Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
Study NCT03148496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biologic Mesh
Description: Biologic mesh placed during surgery
Study NCT02312817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Outreach Invitation
Description: Individuals randomized to Group 2 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic.
Study NCT02312817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Outreach Invitation and Patient Navigation
Description: Individuals randomized to Group 3 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic.
Study NCT03408652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
Study NCT03050671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Pneumatic Compression, Rapid
Description: Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
Study NCT03050671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Pneumatic Compression, Slow
Description: Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
Study NCT00004038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene
Study NCT00004038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT03720730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMA
Description: The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2).
Study NCT01057069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Paclitaxel
Description: Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
Study NCT01057069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin, cyclophosphamide
Description: Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
Study NCT01057069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
Description: One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
Study NCT04061681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BIPAMS)
Description: This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
Study NCT03670914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WatchPAT 200
Description: The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
Study NCT03148496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small Bites
Description: 0.5 cm x 0.5 cm sutures used
Study NCT00052884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00052884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study NCT00052884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00052884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study NCT00052884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT04679259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood
Description: Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
Study NCT04679259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurocognitive test
Description: Neurocognitive test is performed before surgery and at 7 day after surgery
Study NCT04679259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of delirium
Description: Postoperative delirium is assessed daily during 7 days after surgery.
Study NCT00240188 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open mesh repair of ventral incisional hernia
Description: For the open procedure, the technique, as described by Chevrel and others was adopted.
Study NCT00240188 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic mesh repair of ventral incisional hernia
Description: For the laparoscopic repair, the method of Gagner was adopted
Study NCT02128282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: API powder-in-capsule in 200 mg strength.
Study NCT02128282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Study NCT03829592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: misoprostol in a neutral media
Description: giving misoprostol in a neutral media
Study NCT00548223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dengzhan Shengmai capsule
Description: Capsule, 0.18g, 2#, Bid\*1year
Study NCT00548223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsule, 0.18g, 2#, Bid\*1year
Study NCT03829592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol in an acidic media
Description: giving misoprostol in an acidic media
Study NCT03829592 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: misoprostol in an alkaline media
Description: giving misoprostol in an alkaline media
Study NCT04676906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-6861
Description: Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
Study NCT04818437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BALANCE TRAINING
Description: Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
Study NCT00645385 — intervention group
Intervention type: OTHER
Intervention: MRS Spectroscopy
Description: Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI.
Study NCT04676906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-6860
Description: Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
Study NCT04676906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-6891
Description: Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
Study NCT04818437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CORE STABILITY EXERCISES
Description: 1. Abdominal bracing while lying in supine position.~2. Abdominal bracing with heel slide while lying in supine position.~3. Abdominal bracing with Leg lifts while lying in supine position.~4. Abdominal bracing with bridging while lying in supine position.~5. Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying
Study NCT04392557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin / alogliptin Oral Product
Description: 850 or 1000 mg/ 12.5 mg every 12 hours for 12 months
Study NCT03148496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large Bites
Description: 1.0 x 1.0 sutures used
Study NCT03148496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Bites
Description: 1.0 x 1.0 sutures used
Study NCT02964195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: ALFA WASSERMANN S.p.A.
Study NCT03534869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Description: French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.
Study NCT03534869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
Study NCT00922649 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Insulin Pump therapy
Description: Initiation of Insulin pump therapy in patients on >2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
Study NCT01044628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concentrator
Description: Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be >90%
Study NCT01044628 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham concentrator
Description: Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
Study NCT01849783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT01849783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01849783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV
Study NCT01849783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV or PO
Study NCT04392557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin / Pioglitazone Pill
Description: (850 mg/15 mg every 12 hours) for 12 months
Study NCT04392557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple therapy
Description: Metformin / Alogliptin/ Pioglitazone
Study NCT02128282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Study NCT02128282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Study NCT01705860 — intervention group
Intervention type: BIOLOGICAL
Intervention: Santyl
Study NCT00536289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blunt needle
Description: Blunt tipped suture needle
Study NCT00536289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blunt needle
Description: Blunt tipped suture needle
Study NCT03512496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute energy drink - Placebo
Description: Colored water
Study NCT03512496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acute energy drink - Caffein
Description: Sugar free energy drink at 5mg/kg caffeine
Study NCT03512496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Acute energy drink - Decaf
Description: Sugar free decaf energy drink (vitamins only)
Study NCT00946933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NH4Cl (ammonium chloride)
Description: 0.2 g/kg/day of NH4Cl (ammonium chloride)
Study NCT01849783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00958867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program (AT)
Description: Six-month, twice-weekly aerobic training (AT) program
Study NCT00958867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training (RT)
Description: Six-month, twice-weekly resistance training (RT) program
Study NCT00958867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training (S & R; control)
Description: Six-month, twice-weekly stretch \& relax (S \& R; control) program
Study NCT00946933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.025 g/kg/day of NaCl (sodium chloride)
Study NCT01849783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01849783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given PO
Study NCT01849783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT01235884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: 1000000000 CFU per day (5 drops) for 28 days
Study NCT01235884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops daily for 28 days
Study NCT01849783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplant
Study NCT00307177 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
Study NCT02203643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT00126126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBAR Program
Description: Evidence Based Amputee Rehabilitation Program
Study NCT00307177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Baculovirus-expressed Influenza HA vaccine
Description: Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
Study NCT02664259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VBN
Description: VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
Study NCT02664259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VBN
Description: VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
Study NCT02664259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
Study NCT02664259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
Study NCT02203643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02203643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02128282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Study NCT02203643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT04276805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation (tVNS)
Description: a non-invasive and safe technique that transiently enhances brain GABA and noradrenaline levels.
Study NCT04276805 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: cognitive training
Description: A program of regular mental activities purported to maintain or improve one's cognitive abilities.
Study NCT04276805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: A program of regular mental activities purported to maintain or improve one's cognitive abilities.
Study NCT02664259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
Study NCT00841919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine insulin
Description: The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.